Literature DB >> 26614374

Poorly Differentiated Neuroendocrine Tumors.

Jennifer R Eads1.   

Abstract

Poorly differentiated neuroendocrine carcinomas of the gastrointestinal tract are rare and limited data are available to guide treatment. These tumors have been treated akin to small cell lung cancer given the histologic similarities. Their pathology is complex. Over the last decade, these tumors are shown as likely a distinct disease entity that is more heterogeneous than accounted for by the current classification system. This article discusses the epidemiology, prognosis, clinical presentation and pathologic nuances and provides a review of the existing clinical data in poorly differentiated neuroendocrine carcinomas and small cell lung cancers.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  G3; High-grade; Neuroendocrine carcinoma; Neuroendocrine tumor; Poorly differentiated

Mesh:

Substances:

Year:  2016        PMID: 26614374     DOI: 10.1016/j.hoc.2015.09.007

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   2.861


  4 in total

1.  A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy, with Review of the Literature.

Authors:  Andrew T Mertz; Michelle A Ojemuyiwa
Journal:  Case Rep Oncol       Date:  2016-12-14

2.  Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.

Authors:  Jin-Yan Liang; Fan Tong; Fei-Fei Gu; Yang-Yang Liu; Yu-Lan Zeng; Xiao-Hua Hong; Kai Zhang; Li Liu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

3.  ONECUT2 is a driver of neuroendocrine prostate cancer.

Authors:  Haiyang Guo; Xinpei Ci; Musaddeque Ahmed; Junjie Tony Hua; Fraser Soares; Dong Lin; Loredana Puca; Aram Vosoughi; Hui Xue; Estelle Li; Peiran Su; Sujun Chen; Tran Nguyen; Yi Liang; Yuzhe Zhang; Xin Xu; Jing Xu; Anjali V Sheahan; Wail Ba-Alawi; Si Zhang; Osman Mahamud; Ravi N Vellanki; Martin Gleave; Robert G Bristow; Benjamin Haibe-Kains; John T Poirier; Charles M Rudin; Ming-Sound Tsao; Bradly G Wouters; Ladan Fazli; Felix Y Feng; Leigh Ellis; Theo van der Kwast; Alejandro Berlin; Marianne Koritzinsky; Paul C Boutros; Amina Zoubeidi; Himisha Beltran; Yuzhuo Wang; Housheng Hansen He
Journal:  Nat Commun       Date:  2019-01-17       Impact factor: 14.919

4.  Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden.

Authors:  Nai-Wen Kang; Kien-Thiam Tan; Chien-Feng Li; Yu-Hsuan Kuo
Journal:  Curr Oncol       Date:  2021-11-10       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.